07:11 AM EDT, 08/08/2025 (MT Newswires) -- ANI Pharmaceuticals ( ANIP ) reported Q2 adjusted earnings Friday of $1.80 per diluted share, up from $1.02 a year earlier.

Analysts polled by FactSet expected $1.41.

Net revenue for the quarter ended June 30 was $211.4 million, compared with $138 million a year earlier.

Analysts surveyed by FactSet expected $190.1 million.

The company raised its 2025 adjusted diluted EPS guidance to a range of $6.98 to $7.35, from prior outlook of $6.27 to $6.62. Analysts surveyed by FactSet expect $6.53. Full-year revenue is now expected to be in the range of $818 million to $843 million, compared with $768 million to $793 million previously. Analysts surveyed by FactSet expect $791.5 million.

Shares of the company were up more than 7% in recent premarket activity Friday.